left-arrow right-arrow pinterest facebook google_plus linkedin



Recruiting | Phase III

Official Title:

Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose:

To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer.


Group 1 will get FOLFOX and bevacizumab (usual treatment)

Group 2 will get atezolizumab alone (investigational agent only)

Group 3 will receive FOLFOX and bevacizumab plus atezolizumab (usual treatment + investigational drug)

Key Participation Requirements:


Female or Male


19 years and older


Metastatic adenocarcinoma of colon or rectum

Marker Status:

Tumor determined to be mismatch-repair deficient (dMMR) with a panel of all four IHC markers, MLH1, MSH2, PMS2, and MSH6.


No previous chemotherapy or any other systemic therapy for metastatic colorectal cancer is allowed.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:


For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!